CytomegalovirusNCT01248598
The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis
An observational study of Cytomegalovirus and Epstein-Barr Virus Infections, run by Rambam Health Care Campus at 1 site in Israel.
Trial summary
The purpose of this study is to study the prevalence of EBV, HCMV, HHV-6 in saliva and on the toothbrush patient with periodontitis. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Cytomegalovirus, Epstein-Barr Virus Infections, Herpesvirus Infection
- How many people
- 10 participants
- Where
- 1 siteIsrael
- Study dates
- Oct 2010to not given
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient of the Department of Periodontology, School of Graduate Dentistry Rambam Health care campus
Who may be able to join
- Patient with peridontitis
Who cannot join
- Previous periodontal treatment in last 3 month
- Toothbrushing disability
Trial locations and contacts
1 site in 1 country.
Israel1 site, 1 recruiting
- Recruiting
Department of Periodontology, School of Graduate Dentistry Rambam Health care campus
Haifa
Dr. Leon Bilder, 0544598769, leonid.bilder@mail.huji.ac.il
Leon Bilder, DMD
About this study
The purpose of this study is to study the prevalence of EBV, HCMV, HHV-6 in saliva and on the toothbrush patient with periodontitis.
Read the detailed description
Human cytomegalovirus (HCMV), Epstein-Barr virus (EBV) Human Herpes virus6 (HHV-6)
- Medical subject headings
- Epstein-Barr Virus Infections, Herpesviridae Infections
What is being measured
The primary outcome is the main question the study is designed to answer.
The Prevelance Rate of the EBV, HCMV, HHV-6 in saliva
Check the EBV, HCMV, HHV-6 in saliva by PCR
Measured: 1 year
Secondary outcomes (1)
change outcomes EBV, HCMV, HHV-6 in saliva before and after toothbrushing
Check the EBV, HCMV, HHV-6 in saliva by RC-PCR before and after toothbrushing
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Nov 2010 (estimated)
- Study startOct 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CytomegalovirusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rambam Health Care Campus
- Sponsor type
- University, hospital or other
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01248598
- Sponsor's protocol ID
- 400-10-RMB CTIL
- Status last verified
- Oct 2010
- First submitted
- 21 Nov 2010
- Last updated
- 25 Nov 2010
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Nov 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis
- ClinicalTrials.gov ID
- NCT01248598
- Acronym / sponsor ID
- 400-10-RMB CTIL
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Rambam Health Care CampusUniversity, hospital or other
- Study start
- Oct 2010
- First posted
- 25 Nov 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to study the prevalence of EBV, HCMV, HHV-6 in saliva and on the toothbrush patient with periodontitis.
Detailed description
Human cytomegalovirus (HCMV), Epstein-Barr virus (EBV) Human Herpes virus6 (HHV-6)
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient of the Department of Periodontology, School of Graduate Dentistry Rambam Health care campus
Key inclusion criteria (1 listed)
- Patient with peridontitis
Key exclusion criteria (2 listed)
- Previous periodontal treatment in last 3 month
- Toothbrushing disability
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The Prevelance Rate of the EBV, HCMV, HHV-6 in saliva
Time frame: 1 year
Check the EBV, HCMV, HHV-6 in saliva by PCR
1 secondary outcome
change outcomes EBV, HCMV, HHV-6 in saliva before and after toothbrushing
Time frame: 1 year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Nov 2010.
Related trials for Cytomegalovirus
RecruitingObservational study
A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
Cytomegalovirus (CMV)
RecruitingObservational study
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
EBV, HSV
RecruitingPhase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Viral Infection
RecruitingPhase 3
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
Cytomegalovirus (CMV), Kidney Transplant; Complications
RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Cytomegalovirus Prophylaxis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Department of Periodontology, School of Graduate Dentistry Rambam Health care campus
Haifa, Israel
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cytomegalovirus and Epstein-Barr Virus Infections, run by Rambam Health Care Campus at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Nov 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Prevelance Rate of the EBV, HCMV, HHV-6 in saliva (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2010.